Why Do Surgeons Morcellate Tissue, and What Are the Risks?

Morcellation is the process of cutting a large piece of tissue into smaller fragments so it can be pulled out through a tiny surgical incision. The technique became central to minimally invasive gynecologic surgery in the 1990s, when electromechanical devices called power morcellators allowed surgeons to remove bulky uterine fibroids and even entire uteruses through keyhole-sized ports. For most patients the benefits were clear: smaller wounds, faster recovery, less pain. But the procedure became one of the most contentious topics in modern surgery after concerns emerged that morcellating tissue inside the abdomen could scatter undetected cancer cells, turning a curable disease into a potentially fatal one.

Why Tissue Gets Morcellated in the First Place

Uterine fibroids are extremely common noncancerous growths. When they cause pain, heavy bleeding, or pressure symptoms, surgery is often the answer, either removing the fibroids alone (myomectomy) or taking the entire uterus (hysterectomy). Minimally invasive approaches use a few small abdominal incisions rather than one large one. The problem is geometry: a fibroid can easily weigh several hundred grams and measure ten or more centimeters across. It simply will not fit through a port that is one to two centimeters wide. A power morcellator solves this by using a rapidly spinning cylindrical blade to shave tissue into long strips or small chunks inside the abdomen, which can then be suctioned or pulled out piece by piece.

For patients, the payoff of keeping surgery minimally invasive is real. Recovery after laparoscopic surgery is typically faster than after open abdominal surgery, with less blood loss, fewer wound infections, and shorter hospital stays. That practical benefit is what made morcellation so widely adopted and why the debate over its safety is not as simple as “just stop doing it.”

The Hidden Cancer Problem

Fibroids are benign by definition. But a rare uterine cancer called leiomyosarcoma can look almost identical to a fibroid on imaging and during surgery. If a surgeon morcellates what they believe is a fibroid and it turns out to be a sarcoma, the spinning blade can scatter malignant cells across the abdominal and pelvic cavity. That is the core danger.

How often does this happen? Estimates have shifted considerably. In 2014, the U.S. Food and Drug Administration cited a rate of about 1 in 500 surgeries for presumed fibroids harboring an occult leiomyosarcoma. Later meta-analyses found the risk was lower. A meta-analysis pooling data from 64 prospective studies estimated roughly 1 leiomyosarcoma per 8,300 fibroid surgeries, while a broader analysis including retrospective data put the figure closer to 1 in 2,000.¹ Another review noted that the FDA’s original estimate and these newer figures bracket the true range, with the most methodologically rigorous studies landing at the lower end.² A single-center retrospective study of 921 fibroid surgeries found four malignancies overall, including two leiomyosarcomas, giving a rate of about 1 in 460 for leiomyosarcoma specifically at that institution.³

Even the lower estimates mean that across the hundreds of thousands of fibroid surgeries performed each year, some women will have an undiagnosed cancer morcellated. The rarity of the event does not erase the severity of the consequences for the individual patient.

What Happens When a Sarcoma Gets Morcellated

When cancerous tissue is cut up and dispersed inside the abdomen, the clinical picture worsens. A systematic review and meta-analysis found that morcellation of unsuspected leiomyosarcoma was associated with a recurrence rate of about 62%, compared with roughly 39% in patients whose tumors were removed intact. Intra-abdominal recurrence was especially pronounced, rising from about 9% without morcellation to about 39% with it. The death rate was also higher in the morcellated group, at roughly 48% versus 29%.⁴

A separate retrospective cohort study found that morcellation was tied to a more than threefold increase in the risk of recurrence and dramatically shorter recurrence-free survival, roughly 11 months versus 40 months.⁵ Another analysis of stage I leiomyosarcoma cases found an increased adjusted risk of death at one year for the morcellated group, though the study’s authors cautioned that the sample sizes were small and many longer-term comparisons did not reach statistical significance.⁶

The takeaway from these studies is consistent in direction if not in exact magnitude: scattering sarcoma tissue inside the body worsens outcomes. The debate is not really about whether morcellation harms cancer patients. It is about how to prevent the morcellation from happening when no one knows cancer is there.

Benign Complications People Overlook

Cancer risk dominates headlines, but morcellation can cause problems even when the tissue is entirely benign. The spinning blade shaves off small fragments that may be left behind in the abdomen. These fragments can implant on peritoneal surfaces, develop their own blood supply, and grow into what are called parasitic leiomyomas, essentially new fibroids growing in places fibroids have no business being, like the bowel wall or the abdominal sidewall. A systematic review identified 106 cases of parasitic leiomyomas linked to a history of power morcellation, accounting for about 39% of all reported cases of this condition.⁷ These growths can appear months or years after the original surgery and often require another operation to remove.⁸

There is also evidence suggesting that morcellation may contribute to new cases of endometriosis, a painful condition in which tissue similar to the uterine lining grows outside the uterus. A study of more than 5,000 women who had undergone unconfined power morcellation found that roughly 1.3% developed confirmed endometriosis afterward, and among those who went on to a second surgery, about 20% had endometriosis documented for the first time, raising the question of whether scattering uterine tissue played a role.⁹

The FDA Warning and What Changed Afterward

In late 2014, the FDA issued a safety communication discouraging the use of laparoscopic power morcellators for most women undergoing hysterectomy or myomectomy for fibroids.¹⁰ The announcement carried a black-box warning, the agency’s strongest alert, and several hospitals and health systems banned the devices outright.

The warning had immediate and measurable effects on surgical practice. A large analysis of over 75,000 hysterectomies found that after the FDA alert, the rate of open abdominal surgery for fibroid-related hysterectomies rose from about 37% to 43%, while the rate of minimally invasive approaches fell from about 56% to 50%. That shift came with consequences: major complications climbed from roughly 1.9% to 2.4%, and minor complications rose from about 2.7% to 3.3%.¹¹ In other words, more women were being cut open, and more of them were getting hurt in the process. The cure for one risk had introduced another.

A cost-effectiveness analysis modeled the national impact of these practice changes. It found that the shift away from morcellation prevented the accidental morcellation of hundreds of occult cancers, but it also led to an estimated four additional intraoperative deaths and over 1,200 additional major complications. When both sides were weighed together, the net effect still favored the practice changes in terms of quality-adjusted life years, but the tradeoff was far from free.¹²

Contained Morcellation as a Middle Ground

Rather than abandoning morcellation entirely, surgeons have increasingly turned to contained morcellation, where the tissue is placed inside a specimen bag before the power morcellator cuts it. The idea is simple: if fragments stay inside the bag, they cannot implant on abdominal surfaces or scatter cancer cells. In practice, the execution is harder than it sounds.

A 2025 report on a novel tissue containment system described full containment throughout the procedure even during high-volume tissue retrieval.¹³ But not all bags perform equally. Laboratory testing of seven commercially available bags found that leakage pressures varied enormously, and when the forces generated by an active morcellator were factored in, the safety margin dropped sixfold for all brands, with two falling below the threshold where leakage became likely.¹⁴

A systematic review examining transvaginal morcellation within an enclosed bag found that most studies reported no bag ruptures, but a few did. In one study, about a third of the bags had minimal tears, and another found in vitro spillage in nearly a third of a particular bag type. The authors emphasized that it remains unclear whether the leakage was caused by the bag material itself, the extraction technique, or other factors.¹⁵ Contained morcellation is a promising approach, but calling it a solved problem would be premature. The bags are not standardized, some are used off-label, and real-world integrity during a vigorous surgical procedure is hard to guarantee.

Why You Cannot Just Screen for Sarcoma First

The obvious response to the cancer-spreading risk is: figure out if it is cancer before you morcellate. Unfortunately, this is one of the most frustrating gaps in the field. Uterine sarcomas and benign fibroids can look nearly identical on ultrasound and even on MRI. A 2025 review of preoperative diagnostic methods concluded that none of the available tools, including clinical exam, ultrasound, MRI, and biopsy, can definitively distinguish fibroids from sarcomas before surgery.¹⁶

That said, certain clinical features raise the probability that a uterine mass is malignant. A case-control study found several factors independently associated with sarcoma rather than benign fibroids: age 40 or older, postmenopausal status, postmenopausal bleeding, abnormal uterine bleeding, a palpable mass, rapid growth, and a single mass seen on ultrasound. Postmenopausal status carried the most dramatic increase in odds.¹⁷ A population-based study found that the incidence of unexpected sarcoma was somewhat higher in peri- and postmenopausal women undergoing surgery for fibroids than in premenopausal women.¹⁸

The American College of Obstetricians and Gynecologists (ACOG) recommends that before considering morcellation, a patient should be evaluated for signs of increased risk for uterine cancer. If the evaluation raises concern, morcellation is contraindicated. Beyond that, ACOG stresses shared decision-making: the surgeon should walk the patient through the risks and benefits of morcellation, the alternatives, and what is known about the chances of occult malignancy given her specific clinical profile.¹⁹

Manual Alternatives to Power Morcellation

Power morcellation is not the only way to break tissue into smaller pieces. Manual or “cold-knife” morcellation, where the surgeon uses a scalpel rather than a spinning blade, is an older technique that has seen renewed interest. It can be done through a small abdominal incision (minilaparotomy) or through the vagina, often within a containment bag.

A prospective study comparing minilaparotomy extraction with vaginal extraction found no significant differences in pain scores, time to return to normal activities, blood loss, operative time, or complications. Patients in both groups used narcotic pain medication for an average of three days. However, bag tears were more common with the vaginal route, occurring in about 41% of cases compared with about 8% in the minilaparotomy group.²⁰ Manual morcellation is slower than power morcellation but avoids the intense mechanical forces that generate the finest tissue fragments, which is part of the appeal from a safety standpoint.

How the Rotating Blade Creates Spill

Understanding why tissue scatters helps explain both the risk and the engineering challenge. A power morcellator’s rotating cylindrical blade does not simply cut; it exerts torque on the tissue mass, which can cause the specimen to spin. An in vitro study found that the onset of this spinning, and the resulting tissue spill, varied with blade size. Larger blades delayed the spinning effect but produced larger spilled fragments.²¹ The practical implication is that even differences in device design affect how much tissue escapes, making equipment choice and technique both relevant variables in spill risk.

Morcellation Outside Gynecology

While the morcellation debate is loudest in gynecologic surgery, the technique has also been used in urology, particularly for removing kidneys affected by cancer through laparoscopic approaches. In this context, the kidney is placed in an entrapment bag and morcellated inside it to allow extraction through a small incision.

Studies going back to the late 1990s have reported that laparoscopic radical nephrectomy with morcellation appears safe for early-stage kidney cancers. One study with an average follow-up of about 21 months found outcomes comparable to open surgery.²² A later study confirmed that morcellation seemed safe and effective for clinical stage T1 renal cell carcinoma.²³ One important limitation is that morcellation destroys the specimen’s architecture, meaning pathologists can determine the tissue type but cannot assess pathological staging, which limits the technique’s usefulness for certain tumor types.²⁴ In urologic practice, the technique has quietly continued without the same level of controversy seen in gynecology, in part because the kidney is routinely bagged before cutting and the clinical scenario differs.

The Legal Landscape Around Morcellation

The FDA warning did not just change surgical practice. It opened the door to substantial litigation. Gynecologists who continued using power morcellators faced claims alleging that the spread of undiagnosed cancer cells constituted a failure of informed consent or a deviation from the standard of care.²⁵ Court filings have accumulated steadily since the mid-2010s. A review spanning legal databases and court records from 1995 to 2019 found that courts focus on whether surgeons documented their adherence to safety protocols and guidelines, making thorough preoperative counseling and consent documentation a practical necessity for any surgeon still performing the procedure.²⁶

Contained morcellation introduces its own legal wrinkle. Many containment bags used during morcellation are technically off-label, meaning they were not specifically approved for that purpose. This creates a paradox: a surgeon might face liability for not using a containment system (thereby allowing tissue to spread) or for using one off-label (thereby employing an unapproved device).²⁷ For surgeons and patients alike, this ambiguity underscores that morcellation decisions are not purely medical. They exist at the intersection of clinical judgment, regulatory guidance, legal risk, and patient preference, with no single authority offering a clean answer that satisfies all four.

Shared Decision-Making in Practice

Given all of these competing risks, current guidelines from ACOG frame the morcellation question not as a blanket yes-or-no but as a conversation. A clinical decision tool has been developed to help surgeons walk patients through the tradeoffs between laparoscopic surgery with morcellation and open abdominal surgery, laying out complication rates, recovery times, and the estimated probability of occult malignancy for that individual patient’s profile.²⁸ The goal is not to eliminate morcellation but to ensure that when it is used, the patient understands what she is choosing and why.

What makes this conversation difficult is the asymmetry of the outcomes. For the vast majority of patients, morcellation works exactly as intended and they recover quickly from a minimally invasive surgery. For the tiny fraction whose fibroids turn out to be sarcomas, the consequences can be devastating. Patients weighing these odds are essentially asked to compare a high-probability small benefit against a low-probability catastrophic harm, which is the kind of decision that no calculator can make for you.